Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 1,753
- Institution
- Hospital Universitari de Vic
External Links
Identifiers
- ORCID
- 0000-0003-1337-9745
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.